Franklin Biotechnology Discovery Fund

Portfolio Statistics

Assets

Total Fund AssetsAs of 12/31/2020 (updated monthly) $1,537.8 (M)
Net Assets - Class A As of 10/31/2020 (updated monthly) $1,077.7 (M)
P/E Ratio (12-mo Forward)As of 12/31/2020 (updated monthly) 16.13
P/B RatioAs of 12/31/2020 (updated monthly) 6.01

Positions As of 12/31/2020

Portfolio Details

Asset AllocationAs of 12/31/2020

[name] [value]
Equity 97.98%
Cash & Cash Equivalents 2.02%

Geographic BreakdownAs of 12/31/2020

[name] [value]
United States 87.11%
United Kingdom 3.59%
Canada 2.58%
Denmark 2.42%
Cash & Cash Equivalents 2.02%
Switzerland 1.30%
Netherlands 0.98%

sector breakdownAs of 12/31/2020

[name] [value]
Biotechnology 79.87%
Pharmaceuticals 12.88%
Life Sciences Tools & Services 3.97%
Cash & Cash Equivalents 2.02%
Diversified Capital Markets 0.97%
Other Diversified Financial Services 0.29%

TOP TEN HOLDINGSAs of 12/31/2020

40.98%
Other
0% 100%
[holdings-table-heading]
GILEAD SCIENCES INC 5.73%
VERTEX PHARMACEUTICALS INC 5.65%
REGENERON PHARMACEUTICALS INC 4.87%
AMGEN INC 4.77%
IOVANCE BIOTHERAPEUTICS INC 4.21%
ILLUMINA INC 3.97%
GW PHARMACEUTICALS PLC 3.46%
PTC THERAPEUTICS INC 3.04%
SEAGEN INC 2.68%
HORIZON PHARMA PLC 2.60%